Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 546.00K | 588.00K | 684.00K | 689.00K | 665.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 546.00K | 588.00K | 684.00K | 689.00K | 665.00K |
| Cost of Revenue | 41.41M | 39.32M | 36.85M | 34.90M | 33.29M |
| Gross Profit | -40.86M | -38.73M | -36.17M | -34.22M | -32.62M |
| SG&A Expenses | 13.47M | 13.37M | 12.48M | 12.20M | 12.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.88M | 52.69M | 49.34M | 47.10M | 45.30M |
| Operating Income | -54.33M | -52.10M | -48.65M | -46.41M | -44.63M |
| Income Before Tax | -51.02M | -48.85M | -45.43M | -42.98M | -40.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.02 | -48.85 | -45.43 | -42.98 | -40.86 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.02M | -48.85M | -45.43M | -42.98M | -40.86M |
| EBIT | -54.33M | -52.10M | -48.65M | -46.41M | -44.63M |
| EBITDA | -53.95M | -51.71M | -48.25M | -46.00M | -44.21M |
| EPS Basic | -0.88 | -0.94 | -0.96 | -0.95 | -0.91 |
| Normalized Basic EPS | -0.55 | -0.58 | -0.60 | -0.59 | -0.57 |
| EPS Diluted | -0.88 | -0.94 | -0.96 | -0.95 | -0.91 |
| Normalized Diluted EPS | -0.55 | -0.58 | -0.60 | -0.59 | -0.57 |
| Average Basic Shares Outstanding | 234.13M | 212.43M | 190.59M | 181.05M | 178.86M |
| Average Diluted Shares Outstanding | 234.13M | 212.43M | 190.59M | 181.05M | 178.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |